Grifols to invest $360 million to expand its manufacturing capacities for plasma-derived therapies
With these new investments, Grifols increases its production capacity to continue covering the expected growing demand in the plasma-derived products until 2028–2030.
The Board of Directors of Grifols has approved a plan for new industrial investments for the Bioscience division for the period 2016–2021, with the goal of expanding the manufacturing capacity to cover the expected growing demand of plasma-derived products for the upcoming years.
The total amount approved is US Dollars 360 million. The investments will increase the plasma fractionation capacity and purification of the several proteins.
The breakdown of the different projects is as follows:
Plasma fractionation is the process of extracting the different fractions that contain the proteins with therapeutic uses. Afterwards, these fractions are purified and sterilized in specific plants for each of the proteins obtained.
To process the fractions that will be produced in the new plasma fractionation plant, and then obtain the proteins, three new purification and sterile filling plants will need to be constructed for three of the main proteins commercialized by Grifols:
It is scheduled to come into operation in late 2021.
The company schedules to bring forward the construction of this plant to cover the particularly growing market demand of this protein. The construction is scheduled to commence at the end of 2016, so it will begin production in early 2020.
The current purification plants to obtain other plasma proteins such as factor VIII or factor IX have sufficient capacity to absorb the increase that may be generated by this new fractionation plant.
This investment plan considers that the start of new production facilities require an average of approximately 5 years once the investment is approved until the regulatory authorizations are granted to start the commercialization of products.
Grifols estimates that the production capacities will be sufficient to ensure Grifols' ability to cover the expected growing demand in its markets until 2028–2030.
All the projects will be designed and executed by Grifols Engineering, as usual within these types of investments. Grifols Engineering is the in-house company specialized in the construction of this type of facilities. Its wealth of experience gives Grifols a clear competitive advantage, not only in terms of time and obtaining approvals for the new plants but also in relation to the final cost.
Related News
-
News Patients vs Pharma – who will the Inflation Reduction Act affect the most?
The Inflation Reduction Act brought in by the Biden administration in 2022 aims to give better and more equitable access to healthcare in the USA. However, pharma companies are now concerned about the other potential costs of such legislation. -
News CPHI Podcast Series: What does the changing US Pharma market mean for industry and patients alike?
In this week's episode of the CPHI Podcast Series Lucy Chard, Digital Editor for CPHI Online is joined by James Manser to discuss the political and market changes in the US pharma field. -
News CPHI Barcelona Annual Report illuminates industry trends for 2024
The CPHI Annual Survey comes into it’s 7th year to report on the predicted trends for 2024. Over 250 pharma executives were asked 35 questions, with their answers informing the industry landscape for the next year, spanning all major pharma marke... -
News Which 10 drugs are open to price negotiation with Medicare in the USA?
The Centres for Medicare & Medicaid Services, under the Biden administration in the USA, has released a list of the 10 drugs that will be open to price negotiations as part of the new legislation under the Inflation Reduction Act (IRA). -
News EU Medical Devices Regulation causes unintended disappearances of medical devices for children, doctors state
Doctor groups and associations have appealed to the EU to correct the EU Medical Devices Regulation law that may cause unintended shortages of essential drug and medical devices for children and rare disease patients. -
News 10 Major Drug Approvals So Far in 2023
Last year, 37 novel drugs were approved by the FDA, this was a high number for such a category, and covered many fields including oncology, demonstrating how promising further research is, and how it is only continuing to build. To date, there are alre... -
News Detecting Alzheimer's disease with a simple lateral flow test
A novel rapid diagnostic test for early-stage Alzheimer's disease has been developed using a biomarker binder from Aptamer Group along with technology from Neuro-Bio, the neurodegenerative disease experts. -
News CPHI Podcast Series: outsourcing and manufacturing trends
Listen to the CPHI Podcast Series this June to hear Gil Roth of the PBOA speak with Digital Editor Lucy Chard about the biggest trends and topics to watch in pharma outsourcing and manufacturing at the minute.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance